Beigene And Novartis Mutually Terminate The Option Agreement, Effective Immediately To Develop, Manufacture And Commercialize Ociperlimab - 8K
Portfolio Pulse from Benzinga Newsdesk
Beigene and Novartis have mutually agreed to terminate their option agreement to develop, manufacture, and commercialize Ociperlimab, effective immediately.
July 11, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Beigene's partnership with Novartis to develop, manufacture, and commercialize Ociperlimab has been terminated.
The termination of the agreement could potentially impact Beigene's future revenues and growth prospects, as the development, manufacture, and commercialization of Ociperlimab would have provided a new revenue stream.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Novartis' partnership with Beigene to develop, manufacture, and commercialize Ociperlimab has been terminated.
The termination of the agreement could potentially impact Novartis' future revenues and growth prospects, as the development, manufacture, and commercialization of Ociperlimab would have provided a new revenue stream.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100